CNASHighly Regulated (List I)LERCA
NOVAPHARM
Identification
- Active ingredient (INN)
- LERCANIDIPINE CHLORHYDRATE
- Internal code
- 06 E 168
- Country of Origin
- Algeria
- Pharmaceutical form
- Scored Film-coated Tablet
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/30
CNASDAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Lercanidipine is a calcium channel blocker of the dihydropyridine class.
It is sold under various commercial names including Zanidip.
Indications
For the treatment of
Hypertension, management of angina pectoris and Raynaud's syndrome
Pharmacodynamics
Lercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina.
Lercanidipine is similar to other peripheral vasodilators.
Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum.
The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.